Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of colorectal cancer cell lines after treatment with talazoparib

ABSTRACT: Gene expression profiling of colorectal cancer cell lines after treatment with talazoparib

PROVIDER: PRJNA589059 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling of colorectal cancer cell lines after treatment with talazoparib

Project description:We have performed post-treatment gene expression profiling of cell lines to analyze response mechanisms to PARP inhibition.

2020-09-02 | GSE140258 | GEO

Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line

Project description:To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% of the genes deregulated during the treatment with the combination of talazoparib plus romidepsin were from the effect of romidepsin. 94 genes were presented in all three treatment groups and included upregulation of Prdm1, Dusp5, and CD74, among others. Analysis of genes responsible for DNA repair, cell cycle arrest and apoptosis demonstrated the contribution of romidepsin to downregulation of DNA repair, the synergistic effect of romidepsin and talazoparib on downregulation of genes of cell cycle leading to cell cycle arrest, and activation of apoptosis by talazoparib predominantly.

2020-09-04 | GSE157434 | GEO

Folic acid treatment of colorectal cancer cell lines

Project description:Folic acid treatment of colorectal cancer cell lines

| PRJNA772362 | ENA

RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib

Project description:We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib

2020-04-10 | GSE125206 | GEO

Gene expression profiling of human colorectal cancer cell lines [Affymetrix]

Project description:We observed human colorectal cancer cell lines obtained resistance under treatment, and resistant cells switched back to sensitive state when the treatment is withdrawn. To understand gene expressions change during this process, we performed Affymetrix experiments for parental, R20 (resistant), and W20 (withdrawal treatment) clones for three colorectal cancer cell lines.

2024-04-03 | GSE255674 | GEO

Drug treatment of colorectal and endometrial cancer cell lines

Project description:We used expression profiling of colorectal cancer and endometrial cancer cell lines treated with demethylating agents to search for epigenetically regulated miRNAs. The study included three MMR-deficient colorectal cancer cell lines (HCT116, HCT15, and RKO), two MMR-proficient colorectal cancer cell lines (SW480, and T84) and two MMR-deficient endometrial cancer cell lines (AN3CA and HEC59).

2014-12-31 | GSE55930 | GEO

Gene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib

Project description:Triple negative breast cancer and ovarian cancer cell lines were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these transcriptional studies were on the assessment of DNA repair and immune pathway alteration by the therapeutics under study with the aim of defining novel inducers of BRCAness.

2020-05-20 | GSE150298 | GEO

Expression profiling of colorectal cancer cell lines

Project description:Expression profiling of colorectal cancer cell lines

| PRJNA558966 | ENA

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Project description:Germline mutations in BRCA1 or BRCA2 exist in approximately 7% of patients diagnosed with breast cancer and are associated with defects in homologous recombination repair, which has led to the approval of PARP inhibitors for treatment of these cancers in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib for patients with germline BRCA pathogenic variants with a pathologic complete response (pCR) rate of 53%. However, nearly half of the patients treated did not have pCR, thus better strategies are needed to overcome treatment resistance, as well as to identify tumors likely to respond to therapy. To this end, we conducted multi-omic analysis of 13 treatment naïve breast cancer tumors from patients that went on to receive single-agent neoadjuvant talazoparib. We looked for biomarkers that were predictive of response (assessed by residual cancer burden) after 6 months of therapy. We found that all resistant tumors exhibited either the loss of SHLD2, expression of a hypoxia signature, or expression of a stem cell signature. These results indicate that the underlying biology of pre-treatment tumors contain activities that are predictive of response to talazoparib and potentially other PARP inhibitors, and provides a framework that will allow for the better selection of patients for treatment, as well as a roadmap for the development of novel therapies to overcome resistance.

2022-04-30 | GSE160568 | GEO

Expression profiling of colorectal cancer cell lines.

Project description:We have performed genome-wide expression analyses as part of a multi-omics study on 34 colorectal cancer cell lines. The data were used for gene expression subtyping of cell lines, gene set analyses and integration with DNA and protein level data.

2017-07-07 | GSE97023 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data